Attached files

file filename
8-K - 8-K - MAGELLAN HEALTH INCa14-7140_28k.htm

Exhibit 99.1

 

GRAPHIC

 

NEWS RELEASE

Media Contact: Colleen Flanagan Johnson, cefjohnson@magellanhealth.com, (860) 507-1923

Investor Contact: Renie Shapiro, rshapiro@magellanhealth.com, (877) 645-6464

 

Magellan Health Services Reports Fourth Quarter

and Full Year 2013 Financial Results

 

Avon, Conn. — March 3, 2014 — Magellan Health Services, Inc. (NASDAQ: MGLN) today reported financial results for the fourth quarter and full year 2013, as summarized below. For the year ended December 31, 2013, the company reported net revenue of $3.5 billion, segment profit of $259.4 million, and net income of $125.3 million, or $4.53 per diluted common share. Segment profit is equal to net revenues less the sum of cost of care, cost of goods sold, direct service costs and other operating expenses, and includes income from unconsolidated subsidiaries, but excludes income from non-controlling interests held by other parties, as well as stock compensation expense.

 

Financial Results

 

 

 

Three Months Ended December 31

 

Year Ended December 31

 

(Millions, except per share results)

 

2013

 

2012

 

Increase/
(Decrease)

 

2013

 

2012

 

Increase/
(Decrease)

 

Revenue

 

$

1,008.2

 

$

830.3

 

21.4

%

$

3,546.3

 

$

3,207.4

 

10.6

%

Segment Profit

 

55.9

 

77.7

 

(28.1

)%

259.4

 

267.4

 

(3.0

)%

Net Income

 

18.5

 

37.0

 

(50.0

)%

125.3

 

151.0

 

(17.0

)%

Earnings per Share

 

0.67

 

1.32

 

(49.2

)%

4.53

 

5.42

 

(16.4

)%

 

As of December 31, 2013, the company had unrestricted cash and investments of $261.4 million.

 

“Magellan Health Services is a very different company today than it was a year ago,” said Barry M. Smith, chairman and chief executive officer of Magellan Health Services. “While our core businesses continue to perform admirably, we have made significant advancements in our two strategic initiatives. Magellan Complete Care is operational and continues to expand. In addition, we now have a single, integrated and growing pharmacy operation with a complete set of product offerings. The two acquisitions completed last year, Partners Rx and AlphaCare, have given us additional scale, capabilities, and market focus to further these strategies.

 

“In addition, we’ve implemented changes to our operations and products to ensure that Magellan is nimble, competitive and poised to respond quickly to the changing health care marketplace. We are moving closer to our vision of becoming a growth company.”

 

Outlook

 

“Magellan Health Services posted solid financial results during 2013, and the continued progress on our strategic growth initiatives will position us for future success,” said Jonathan N. Rubin, chief financial officer. “Additionally,

 



 

while we continue to invest in our business, we also returned capital to shareholders through our share repurchase program.

 

“Relative to 2014, we are maintaining the ranges discussed in our December guidance call for net revenue of $3.6 billion to $3.8 billion, net income of $57 million to $73 million, and segment profit of $215 million to $235 million. We are also maintaining our guidance for cash flow from operations in the range of $181 million to $203 million. Taking into account the impact of share repurchase activity through February 26, 2014, but not considering any potential future share repurchases, our guidance range for fully diluted EPS is estimated to be $2.02 to $2.58 per fully diluted share.”

 

Earnings Results Conference Call

 

Management will host a conference call at 10:00 a.m. Eastern Time on Monday, March 3, 2014. To participate in the conference call, interested parties should call 1-800-857-1812 and reference the pass code Fourth Quarter Earnings Call 2013 approximately 15 minutes before the start of the call. The conference call will also be available via a live webcast at Magellan’s Investor Relations page at www.MagellanHealth.com.

 

About Magellan Health Services: Headquartered in Avon, Conn., Magellan Health Services Inc. is a health care management company that focuses on fast-growing, complex and high-cost areas of health care, with an emphasis on special population management. Magellan delivers innovative solutions to improve quality outcomes and optimize the cost of care for those we serve. Magellan’s customers include health plans, managed care organizations, insurance companies, employers, labor unions, various military and government agencies, third party administrators, and brokers.  As of December 31, 2013, the company served approximately 34.3 million members in our managed healthcare segments and 17.7 million members in our specialty solutions segment. Our pharmacy management segment processed over 69 million adjusted claims on behalf of 0.4 million commercial PBM members, 9.5 million medical pharmacy members and 25 states and the District of Columbia in our PBA business.  For more information, visit www.MagellanHealth.com.

 

Cautionary Statement

 

This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties.  All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding estimates of 2014 net revenue, net income, segment profit, cash flow from operations, earnings per share, growth and strategy. These statements are based on management’s analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company’s customers to manage the health care services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company’s risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for Medicaid contracts; termination or non-renewal of customer contracts; the impact of new or amended laws or regulations; governmental inquiries; litigation; competition; operational issues; health care reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the company’s Annual Report on Form 10-K for the year

 



 

ended December 31, 2012, filed with the Securities and Exchange Commission on February 28, 2013, the company’s subsequent Quarterly Reports on Form 10-Q filed during 2013 and the company’s Annual Report on Form 10-K for the year ended December 31, 2013, expected to be filed with the Securities and Exchange Commission and posted on the company’s website later today.  Readers are cautioned not to place undue reliance on these forward-looking statements. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release. Segment profit information referred to herein may be considered a non-GAAP financial measure.  Further information regarding this measure, including the reasons management considers this information useful to investors, are included in the company’s most recent Annual Report on Form 10-K and on subsequent Form 10-Qs.

 

# # #

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, except per share amounts)

 

 

 

Three Months Ended December 31,

 

Year Ended December 31,

 

 

 

2012

 

2013 (1)

 

2012

 

2013 (1)

 

 

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue:

 

 

 

 

 

 

 

 

 

Managed care and other

 

$

742,950

 

$

823,627

 

$

2,857,099

 

$

3,063,049

 

PBM and dispensing

 

87,324

 

184,583

 

350,298

 

483,268

 

Total net revenue

 

830,274

 

1,008,210

 

3,207,397

 

3,546,317

 

 

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

Cost of care

 

528,529

 

605,782

 

2,071,890

 

2,232,976

 

Cost of goods sold

 

82,859

 

174,411

 

328,414

 

455,601

 

Direct service costs and other operating expenses (2) 

 

145,016

 

178,588

 

557,512

 

619,546

 

Depreciation and amortization

 

15,316

 

21,224

 

60,488

 

71,994

 

Interest expense

 

534

 

809

 

2,247

 

3,000

 

Interest and other income

 

(400

)

(983

)

(2,019

)

(1,985

)

Total costs and expenses

 

771,854

 

979,831

 

3,018,532

 

3,381,132

 

Income before income taxes

 

58,420

 

28,379

 

188,865

 

165,185

 

Provision for income taxes

 

21,418

 

9,888

 

37,838

 

39,924

 

Net income

 

37,002

 

18,491

 

151,027

 

125,261

 

Other comprehensive (loss) income (3) 

 

(93

)

(21

)

115

 

(58

)

Comprehensive income

 

$

36,909

 

$

18,470

 

$

151,142

 

$

125,203

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding — basic

 

27,505

 

27,285

 

27,386

 

27,054

 

Weighted average number of common shares outstanding — diluted

 

28,020

 

28,008

 

27,882

 

27,675

 

 

 

 

 

 

 

 

 

 

 

Net income per common share — basic

 

$

1.35

 

$

0.68

 

$

5.51

 

$

4.63

 

Net income per common share — diluted

 

$

1.32

 

$

0.67

 

$

5.42

 

$

4.53

 

 


(1) For a more detailed discussion of Magellan’s results for the year ended December 31, 2013, refer to the Company’s Annual Report on Form 10-K, which will be filed with the SEC on Monday, March 3, 2014, and the live broadcast or taped replay of the Company’s earnings conference call on Monday, March 3, 2014, which will be available at www.MagellanHealth.com.

 

(2) Includes stock compensation expense of $3,848 and $6,488 for the three months ended December 31, 2012 and 2013, respectively, and $17,783 and $21,252 for the years ended December 31, 2012 and 2013, respectively.

 

(3) Net of income tax (benefit) provision of $(61) and $(13) for the three months ended December 31, 2012 and 2013, respectively, and $73 and $(38) for the years ended December 31, 2012 and 2013, respectively.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

 

 

Year Ended December 31,

 

 

 

2012

 

2013 (1)

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

Net income

 

$

151,027

 

$

125,261

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

60,488

 

71,994

 

Non-cash interest expense

 

728

 

736

 

Non-cash stock compensation expense

 

17,783

 

21,252

 

Non-cash income tax expense (benefits)

 

17,306

 

(1,212

)

Non-cash amortization on investments

 

7,193

 

9,107

 

Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:

 

 

 

 

 

Restricted cash (2) 

 

(40,760

)

(2,242

)

Accounts receivable, net

 

(16,411

)

(40,804

)

Pharmaceutical inventory

 

(6,160

)

(3,882

)

Other assets

 

414

 

(9,293

)

Accounts payable and accrued liabilities

 

(8,321

)

3,593

 

Medical claims payable and other medical liabilities

 

31,292

 

17,866

 

Tax contingencies

 

(35,376

)

(22,960

)

Deferred credits and other long-term liabilities

 

1,901

 

10,988

 

Other

 

189

 

2,757

 

Net cash provided by operating activities

 

181,293

 

183,161

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Capital expenditures

 

(69,549

)

(64,542

)

Acquisitions and investments in businesses, net of cash acquired

 

 

(107,541

)

Purchase of investments

 

(321,541

)

(323,253

)

Maturity of investments

 

281,748

 

339,428

 

Other

 

(1,225

)

 

Net cash used in investing activities

 

(110,567

)

(155,908

)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Payments on long-term debt and capital lease obligations

 

 

(3,001

)

Payments to acquire treasury stock

 

(21,868

)

(60,677

)

Proceeds from exercise of stock options and warrants

 

20,486

 

47,529

 

Tax benefit from exercise of stock options and vesting of stock awards

 

990

 

3,212

 

Other

 

(732

)

(593

)

Net cash used in financing activities

 

(1,124

)

(13,530

)

 

 

 

 

 

 

Net increase in cash and cash equivalents

 

69,602

 

13,723

 

Cash and cash equivalents at beginning of period

 

119,862

 

189,464

 

Cash and cash equivalents at end of period

 

$

189,464

 

$

203,187

 

 


(1) The Company’s Annual Report on Form 10-K for the year ended December 31, 2013 will be filed with the SEC on Monday, March 3, 2014.

 

(2) Includes the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change.  During the year ended December 31, 2012, restricted investments of $16,660 were shifted to restricted cash that resulted in an operating cash flow use, with restricted cash of $29,208 shifted to restricted investments during the year ended December 31, 2013 that resulted in an operating cash flow source.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT

(In thousands)

 

 

 

Three Months Ended December 31,

 

Year Ended December 31,

 

 

 

2012

 

2013 (1)

 

2012

 

2013 (1)

 

 

 

(Unaudited)

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Managed care and other revenue

 

 

 

 

 

 

 

 

 

- Commercial

 

$

193,048

 

$

188,811

 

$

728,512

 

$

766,841

 

- Public Sector

 

414,586

 

491,194

 

1,620,875

 

1,757,933

 

- Specialty Solutions

 

95,324

 

98,700

 

349,133

 

375,818

 

- Pharmacy Management (2)

 

55,823

 

62,613

 

227,669

 

228,705

 

- Elimination (2) 

 

(15,831

)

(17,691

)

(69,090

)

(66,248

)

Total managed care and other revenue

 

742,950

 

823,627

 

2,857,099

 

3,063,049

 

 

 

 

 

 

 

 

 

 

 

PBM and dispensing revenue - Pharmacy Management

 

87,324

 

184,583

 

350,298

 

483,268

 

 

 

 

 

 

 

 

 

 

 

Cost of care

 

 

 

 

 

 

 

 

 

- Commercial

 

113,526

 

114,958

 

437,518

 

469,478

 

- Public Sector (2) 

 

354,936

 

427,329

 

1,413,320

 

1,523,023

 

- Specialty Solutions

 

62,019

 

65,284

 

228,383

 

247,496

 

- Pharmacy Management

 

13,879

 

15,902

 

61,759

 

59,227

 

- Elimination (2) 

 

(15,831

)

(17,691

)

(69,090

)

(66,248

)

Total cost of care

 

528,529

 

605,782

 

2,071,890

 

2,232,976

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold - Pharmacy Management

 

82,859

 

174,411

 

328,414

 

455,601

 

 

 

 

 

 

 

 

 

 

 

Direct service costs and other operating expenses

 

 

 

 

 

 

 

 

 

- Commercial

 

44,210

 

42,668

 

172,035

 

172,491

 

- Public Sector

 

22,279

 

40,416

 

89,129

 

122,819

 

- Specialty Solutions

 

14,305

 

16,110

 

55,418

 

57,334

 

- Pharmacy Management

 

28,061

 

35,211

 

111,593

 

128,427

 

- Corporate

 

36,161

 

44,183

 

129,337

 

138,475

 

Total direct service costs and other operating expenses

 

145,016

 

178,588

 

557,512

 

619,546

 

 

 

 

 

 

 

 

 

 

 

Stock compensation expense (3)

 

 

 

 

 

 

 

 

 

- Commercial

 

298

 

(113

)

(532

)

(503

)

- Public Sector

 

(276

)

(205

)

(1,111

)

(1,038

)

- Specialty Solutions

 

(388

)

(355

)

(1,567

)

(1,630

)

- Pharmacy Management

 

(303

)

(274

)

(1,007

)

(1,172

)

- Corporate

 

(3,179

)

(5,541

)

(13,566

)

(16,909

)

Total stock compensation expense

 

(3,848

)

(6,488

)

(17,783

)

(21,252

)

 

 

 

 

 

 

 

 

 

 

Segment profit (loss)

 

 

 

 

 

 

 

 

 

- Commercial

 

35,014

 

31,298

 

119,491

 

125,375

 

- Public Sector

 

37,647

 

23,654

 

119,537

 

113,129

 

- Specialty Solutions

 

19,388

 

17,661

 

66,899

 

72,618

 

- Pharmacy Management

 

18,651

 

21,946

 

77,208

 

69,890

 

- Corporate and Elimination

 

(32,982

)

(38,642

)

(115,771

)

(121,566

)

Total segment profit

 

$

77,718

 

$

55,917

 

$

267,364

 

$

259,446

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of segment profit to income before income taxes:

 

 

 

 

 

 

 

 

 

Segment profit

 

$

77,718

 

$

55,917

 

$

267,364

 

$

259,446

 

Stock compensation expense

 

(3,848

)

(6,488

)

(17,783

)

(21,252

)

Depreciation and amortization

 

(15,316

)

(21,224

)

(60,488

)

(71,994

)

Interest expense

 

(534

)

(809

)

(2,247

)

(3,000

)

Interest and other income

 

400

 

983

 

2,019

 

1,985

 

Income before income taxes

 

$

58,420

 

$

28,379

 

$

188,865

 

$

165,185

 

 


(1) The Company’s Form 10-K for the year ended December 31, 2013 will be filed with the SEC on Monday, March 3, 2014.

 

(2) Public Sector subcontracts with Pharmacy Management to provide pharmacy benefits management services for certain of Public Sector’s customers. As such, revenue and cost of care related to this intersegment arrangement are eliminated.

 

(3) Stock compensation expense is included in direct service costs and other operating expenses; however, this amount is excluded from the computation of segment profit since it is managed on a consolidated basis.